GEN Exclusives

More »

GEN News Highlights

More »
Jan 18, 2007

NicOx Achieves First Milestone of Euro 5M From Merck

  • NicOx initiated GLP toxicology studies on the first antihypertensive candidate selected along with Merck & Co., according to a deal between the two firms. NicOx thus received its first milestone of Euro 5 million.

    NicOx and Merck have been working together since March 2006 to develop and commercialize new antihypertensive drugs using NicOx' nitric oxide-donating technology for the treatment of high blood pressure, complications of hypertension, and other cardiovascular and related disorders.

    NicOx previously received Euro 9.2 million from Merck and stands to receive Euro 274 million in future potential milestone payments.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?